GlycoMimetics postpones $60 million IPO

By Renaissance Capital,

Shutterstock photo

GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, postponed its IPO on Friday. The Gaithersburg, MD-based company was founded in 2003 and booked $12 million in sales for the 12 months ended June 30, 2013. GlycoMimetics initially filed confidentially on August 21, 2013. Jefferies & Co. and Barclays were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: GLYC

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by